Role of cerebral hypoperfusion in multiple sclerosis (ROCHIMS): study protocol for a proof-of-concept randomized controlled trial with bosentan

DiscussionWe hypothesize that restoring cerebral hypoperfusion in MS patients improves axonal metabolism.Early positive effects on fatigue and cognitive dysfunction related to MS might additionally be detected. There is a medical need for drugs that can slow down the progressive axonal degeneration in MS, making this an important topic of interest.Trial registrationClinical Trials Register, EudraCT2017-001253-13. Registered on 15 February 2018.
Source: Trials - Category: Research Source Type: clinical trials